Insider, hier zie:
http://etfdailynews.com/2013/09/04/4-bi ... 0-or-more/" onclick="window.open(this.href);return false;

Evita thx : ik zit in het buitenland en zal het vanavond eens lezen.

Toch goed nieuws ivm IMUC, vandaar waarschijnlijk de koersstijging van gisteren:
http://seekingalpha.com/article/1835412 ... e_readmore" onclick="window.open(this.href);return false;

Evita : IMUC gaat er komen ! mark my words !

lees maar effe deze post : een wijs man !
als je winst hebt en de winst is significant : cashen !
http://finance.yahoo.com/mbview/threadv ... Cd%2C9%2C3" onclick="window.open(this.href);return false;

en dit is waarom ik dat zeg : een winst van +/- 47 % OP 1 DAG !
http://finance.yahoo.com/q?s=imuc&ql=1" onclick="window.open(this.href);return false;

vandaag 2/3 verkocht met 80 % winst op 2j tijd

Bedankt Insider voor de nuttige info die je hier plaatst

@janv : goed gedaan! Waar gaan we eten?
edit : op uw kosten hé ! LOL

De teerling is geworden: IMUC is over and out, time to move on...

Yep, over en out denk ik ook.

ImmunoCellular Therapeutics Ltd. IMUC shares dropped more than 55% to $1.22 a share after the company said its mid-stage study of a brain-tumor treatment did not show a statistical improvement in patient survival rates.

4:00 pm ImmunoCellular Therapeutics Phase II study demonstrates that glioblastoma patients live longer without disease progression when treated with ICT-107; the differences in the overall survival (:OS) K-M curves did not reach statistical significance (IMUC) : IMUC announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (:GBM) in its randomized, placebo-controlled phase II trial. A comparison of PFS between ICT-107 and placebo showed a statistically significant difference in the Kaplan-Meier (K-M) curves favoring ICT-107 in the intent-to-treat population of all 124 randomized patients. The difference in the median progression-free survival times between ICT-107 and placebo favored ICT-107 and was two months in duration.

The differences in the overall survival (:OS) K-M curves did not reach statistical significance in the intent-to-treat population (the primary endpoint) or the per-protocol population. However, there were numerical differences in the median survivals favoring ICT-107 of two months in the intent-to-treat population and three months in the per-protocol population.

The OS analysis includes data on 67 events (patient deaths) out of a possible 124, whereas the PFS analysis includes data from 103 events. ImmunoCellular Therapeutics plans to continue following patients in this trial to collect more mature OS data. In the matured data from the open label, phase I trial, the Company observed a consistent benefit in both PFS and OS compared with historical controls, and on this basis thinks that it is possible that the primary OS benefit could be clarified as the phase II data mature. In this phase II study, ICT-107 was generally safe and well tolerated, with no imbalance of adverse events between the active and placebo groups.

aiiiiiiiiiiiiiiiiiiiii.... time to bail out !

Insider, dat is slecht nieuws ! Hoe best straks verkopen ? Marktprijs instellen ?

evita schreef:Insider, dat is slecht nieuws ! Hoe best straks verkopen ? Marktprijs instellen ?

ik denk dat dit de enige oplossing zal zijn want het zal als een meteoor neergaan ... of Pre-market al de boel verkopen ...

insider schreef:

evita schreef:Insider, dat is slecht nieuws ! Hoe best straks verkopen ? Marktprijs instellen ?

ik denk dat dit de enige oplossing zal zijn want het zal als een meteoor neergaan ... of Pre-market al de boel verkopen ...

Ik kan niet Pre-market verkopen !

Evita : het zal niet veel uitmaken .... dalen gaat IMUC sowieso doen ...